StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a report issued on Thursday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Down 4.3 %

NASDAQ:CHEK opened at $0.86 on Thursday. The company has a market cap of $5.04 million, a PE ratio of -0.29 and a beta of 0.16. The business’s 50 day moving average is $1.09 and its two-hundred day moving average is $1.32. Check-Cap has a 52 week low of $0.56 and a 52 week high of $3.45.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.